{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T22:59:35Z","timestamp":1789340375047,"version":"build-2803163510"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T00:00:00Z","timestamp":1508803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI068632"],"award-info":[{"award-number":["UM1AI068632"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI068616"],"award-info":[{"award-number":["UM1AI068616"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI106716"],"award-info":[{"award-number":["UM1AI106716"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P30 AI027763"],"award-info":[{"award-number":["P30 AI027763"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R01 HD068174"],"award-info":[{"award-number":["R01 HD068174"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0186589","type":"journal-article","created":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T18:08:30Z","timestamp":1508868510000},"page":"e0186589","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2702-4486","authenticated-orcid":true,"given":"Liusheng","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane C.","family":"Lindsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Marzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gingrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobbie","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Barlow-Mosha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phionah K.","family":"Ssemambo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Portia","family":"Kamthunzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Nachman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca T.","family":"Aweeka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the IMPAACT P1079 protocol team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,10,24]]},"reference":[{"key":"ref1","unstructured":"Malaria biology. [Internet]. [cited November 23, 2016]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.cdc.gov\/malaria\/about\/biology\/index.html\" xlink:type=\"simple\">http:\/\/www.cdc.gov\/malaria\/about\/biology\/index.html<\/ext-link>."},{"key":"ref2","unstructured":"World Malaria Report 2015. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/malaria\/publications\/world-malaria-report-2015\/wmr2015-without-profiles.pdf?ua=1\" xlink:type=\"simple\">http:\/\/www.who.int\/malaria\/publications\/world-malaria-report-2015\/wmr2015-without-profiles.pdf?ua=1<\/ext-link>. Accessed on December 28, 2015. [Internet]. 2015."},{"key":"ref3","unstructured":"HIV\/AIDS, Data and Statistics. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/hiv\/data\/en\/\" xlink:type=\"simple\">http:\/\/www.who.int\/hiv\/data\/en\/<\/ext-link>. Accessed on December 28, 2015. [Internet]."},{"issue":"Suppl 1","key":"ref4","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1475-2875-8-S1-S5","article-title":"The clinical efficacy of artemether\/lumefantrine (Coartem)","volume":"8","author":"M Makanga","year":"2009","journal-title":"Malaria journal"},{"key":"ref5","unstructured":"WHO. Antiretroviral therapy for HIV infection in infants and children: Towards universal access. Recommendations for a public health approach, 2010 revision. World Health Organization website: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/apps.who.int\/iris\/bitstream\/10665\/164255\/1\/9789241599801_eng.pdf?ua=1\" xlink:type=\"simple\">http:\/\/apps.who.int\/iris\/bitstream\/10665\/164255\/1\/9789241599801_eng.pdf?ua=1<\/ext-link>; accessed on August 30, 2017."},{"key":"ref6","unstructured":"WHO. Consolidated Guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, Recommendations for a public health approach, 2nd edition, 2016. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/apps.who.int\/iris\/bitstream\/10665\/208825\/1\/9789241549684_eng.pdf\" xlink:type=\"simple\">apps.who.int\/iris\/bitstream\/10665\/208825\/1\/9789241549684_eng.pdf<\/ext-link>, accessed on Sept 1, 2017. p. 97."},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/QAI.0b013e31826ebb5c","article-title":"Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers","volume":"61","author":"L Huang","year":"2012","journal-title":"Journal of acquired immune deficiency syndromes"},{"issue":"4","key":"ref8","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/QAI.0b013e3181acb4ff","article-title":"Lopinavir\/ritonavir affects pharmacokinetic exposure of artemether\/lumefantrine in HIV-uninfected healthy volunteers","volume":"51","author":"P German","year":"2009","journal-title":"Journal of acquired immune deficiency syndromes"},{"issue":"9","key":"ref9","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1093\/jac\/dks207","article-title":"Significant pharmacokinetic interactions between artemether\/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults","volume":"67","author":"P Byakika-Kibwika","year":"2012","journal-title":"The Journal of antimicrobial chemotherapy"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/1475-2875-13-205","article-title":"Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy","volume":"13","author":"BA Maganda","year":"2014","journal-title":"Malaria journal"},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/bcp.12529","article-title":"Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications","volume":"79","author":"RM Hoglund","year":"2015","journal-title":"British journal of clinical pharmacology"},{"issue":"5","key":"ref12","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/jac\/dkr596","article-title":"Lopinavir\/ritonavir significantly influences pharmacokinetic exposure of artemether\/lumefantrine in HIV-infected Ugandan adults","volume":"67","author":"P Byakika-Kibwika","year":"2012","journal-title":"The Journal of antimicrobial chemotherapy"},{"issue":"12","key":"ref13","doi-asserted-by":"crossref","first-page":"7852","DOI":"10.1128\/AAC.01153-15","article-title":"Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy","volume":"59","author":"S Parikh","year":"2015","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"12","key":"ref14","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1128\/AAC.05265-11","article-title":"Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients","volume":"55","author":"T Kredo","year":"2011","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1128\/AAC.00679-09","article-title":"Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda","volume":"54","author":"J Mwesigwa","year":"2010","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1293.2007.00426.x","article-title":"Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review","volume":"8","author":"CL Cooper","year":"2007","journal-title":"HIV medicine"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-3156.2006.01784.x","article-title":"How much fat is necessary to optimize lumefantrine oral bioavailability?","volume":"12","author":"EA Ashley","year":"2007","journal-title":"Tropical medicine & international health: TM & IH"},{"issue":"12","key":"ref18","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.4155\/bio.13.91","article-title":"Determination of artemether and dihydroartemisinin in human plasma with a new hydrogen peroxide stabilization method","volume":"5","author":"L Huang","year":"2013","journal-title":"Bioanalysis"},{"issue":"2","key":"ref19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4155\/bio.11.303","article-title":"Determination of lumefantrine in small-volume human plasma by LC-MS\/MS: using a deuterated lumefantrine to overcome matrix effect and ionization saturation","volume":"4","author":"L Huang","year":"2012","journal-title":"Bioanalysis"},{"key":"ref20","unstructured":"Clinical Pharmacology Quality Assurance (CPQA) program. CPQA guidelines for chromatographic method development and validation based on (and including) FDA guidelines dated May, 2001. Version 4.0 (2012)."},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4155\/bio.09.6","article-title":"A liquid chromatographic-tandem mass spectrometric method for determination of artemether and its metabolite dihydroartemisinin in human plasma","volume":"1","author":"W Hanpithakpong","year":"2009","journal-title":"Bioanalysis"},{"issue":"5","key":"ref22","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jpba.2009.06.051","article-title":"Development and validation of a high-performance liquid chromatography\/tandem mass spectrometry method for the determination of artemether and its active metabolite dihydroartemisinin in human plasma","volume":"50","author":"L Huang","year":"2009","journal-title":"Journal of pharmaceutical and biomedical analysis"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4137\/ACI.S4431","article-title":"A modified method for determination of lumefantrine in human plasma by HPLC-UV and combination of protein precipitation and solid-phase extraction: application to a pharmacokinetic study","volume":"5","author":"L Huang","year":"2010","journal-title":"Analytical chemistry insights"},{"issue":"3","key":"ref24","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/cid\/ciw291","article-title":"Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children","volume":"63","author":"S Parikh","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"12","key":"ref25","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/S0090-9556(24)14960-4","article-title":"Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450","volume":"27","author":"DA Erickson","year":"1999","journal-title":"Drug metabolism and disposition: the biological fate of chemicals"},{"issue":"4","key":"ref26","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2125.2008.03198.x","article-title":"Maraviroc: in vitro assessment of drug-drug interaction potential","volume":"66","author":"R Hyland","year":"2008","journal-title":"British journal of clinical pharmacology"},{"issue":"Suppl 1","key":"ref27","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-2125.2008.03136.x","article-title":"A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects","volume":"65","author":"AL Pozniak","year":"2008","journal-title":"British journal of clinical pharmacology"},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00003088-199937020-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine","volume":"37","author":"NJ White","year":"1999","journal-title":"Clinical pharmacokinetics"},{"issue":"5","key":"ref29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/bcpt.12714","article-title":"Oil-Fortified Maize Porridge Increases Absorption of Lumefantrine in Children with Uncomplicated Falciparum Malaria","volume":"120","author":"N Mwebaza","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13643-017-0567-7","article-title":"Choice of initial antiretroviral drugs and treatment outcomes among HIV-infected patients in sub-Saharan Africa: systematic review and meta-analysis of observational studies","volume":"6","author":"TA Ayele","year":"2017","journal-title":"Syst Rev"},{"issue":"6","key":"ref31","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/INF.0000000000001505","article-title":"Virologic Response to First-line Efavirenz- or Nevirapine-based Antiretroviral Therapy in HIV-infected African Children","volume":"36","author":"A Kekitiinwa","year":"2017","journal-title":"Pediatr Infect Dis J"},{"issue":"22","key":"ref32","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa1200501","article-title":"Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children","volume":"367","author":"J Achan","year":"2012","journal-title":"The New England journal of medicine"},{"issue":"4","key":"ref33","doi-asserted-by":"crossref","first-page":"ofw217","DOI":"10.1093\/ofid\/ofw217","article-title":"Parasite Clearance and Artemether Pharmacokinetics Parameters Over the Course of Artemether-Lumefantrine Treatment for Malaria in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Ugandan Children","volume":"3","author":"R Kajubi","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"ref34","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S1473-3099(15)70024-1","article-title":"The effect of dose on the antimalarial efficacy of artemether-lumefantrine: a systematic review and pooled analysis of individual patient data","volume":"15","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"ref35","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/infdis\/jiu491","article-title":"Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia","volume":"211","author":"S Takala-Harrison","year":"2015","journal-title":"J Infect Dis"},{"issue":"5","key":"ref36","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1314981","article-title":"Spread of artemisinin resistance in Plasmodium falciparum malaria","volume":"371","author":"EA Ashley","year":"2014","journal-title":"The New England journal of medicine"},{"issue":"5","key":"ref37","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMoa0808859","article-title":"Artemisinin resistance in Plasmodium falciparum malaria","volume":"361","author":"AM Dondorp","year":"2009","journal-title":"The New England journal of medicine"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0186589","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T18:31:40Z","timestamp":1750962700000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0186589"}},"subtitle":[],"editor":[{"given":"Sarah L.","family":"Pett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,10,24]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,10,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0186589","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,24]]}}}